Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: new indications?

B Combe1

  • 1Rheumatology Federation, Hôpital Lapeyronie, Montpellier, France. combe@montp.inserm.fr

Joint Bone Spine
|January 26, 2002
PubMed
Summary
This summary is machine-generated.

Thalidomide, once withdrawn due to birth defects, is now used for skin conditions and shows potential in treating inflammatory diseases and cancers due to its anti-angiogenic properties.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease-modifying drug retention rate according to patient age in patients with early rheumatoid arthritis: analysis of the ESPOIR cohort.

Rheumatology international·2021
Same author

Predictors of fatigue and persistent fatigue in early rheumatoid arthritis: a longitudinal observational study, data from the ESPOIR cohort.

Scandinavian journal of rheumatology·2020
Same author

Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients.

Arthritis research & therapy·2020
Same author

The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

Translational medicine @ UniSa·2019
Same author

Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2018
Same author

Chikungunya Virus-Associated Disease.

Current rheumatology reports·2017

Area of Science:

  • Pharmacology
  • Immunology
  • Oncology

Background:

  • Thalidomide, initially a sedative, was withdrawn in 1961 due to severe birth defects.
  • Reintroduced for specific dermatological conditions like erythema nodosum and mucosal ulcers.
  • Emerging research highlights its immunomodulatory and anti-angiogenic effects.

Purpose of the Study:

  • To review the re-emergence and expanded therapeutic applications of thalidomide.
  • To explore its potential in inflammatory and neoplastic diseases based on novel pharmacological insights.
  • To assess its efficacy and side effects in various systemic disorders.

Main Methods:

  • Review of existing literature, including open-label studies and case reports.
  • Analysis of thalidomide's pharmacological properties: cytokine modulation (TNF-alpha) and angiogenesis inhibition.

Related Experiment Videos

  • Evaluation of clinical outcomes and side effects in patients with various systemic conditions.

    • Main Results:

    • Thalidomide is effective for certain skin diseases and has shown promise in Crohn's disease, rheumatoid arthritis, and other systemic disorders.
    • Common side effects were observed, often dose-limiting.
    • Anti-angiogenic properties suggest potential in cancer therapy, including multiple myeloma and metastatic disease.

    Conclusions:

    • Thalidomide has evolved from a withdrawn sedative to a valuable therapeutic agent for specific conditions.
    • Its immunomodulatory and anti-angiogenic effects warrant further investigation for inflammatory and neoplastic diseases.
    • Development of thalidomide analogs with improved safety profiles is ongoing.